Early Recognition of Invasive Candidiasis in the ICU

  • P.-E. Charles
  • R. Bruyere
  • F. Dalle
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM, volume 2012)


Invasive candidiasis, mainly due to Candida albicans, is a life-threatening complication encountered in intensive care units (ICUs) [1, 2]. Candida spp. is regularly reported as the fourth most frequent microbial agent responsible for blood-borne infections in ICU-acquired sepsis [3, 4]. Moreover, cumulative evidence supports the fact that the incidence of invasive candidiasis is increasing. In addition, an epidemiological shift, namely the emergence of non-albicans species against which azoles are often less effective, has been reported over the past two decades [5].


Invasive Candidiasis Fungal Colonization Invasive Fungal Disease Hematopoietic Stem Cell Transplant Recipient Candida Colonization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3: 685–702PubMedCrossRefGoogle Scholar
  2. 2.
    Falagas ME, Apostolou KE, Pappas VD (2006) Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 25: 419–425PubMedCrossRefGoogle Scholar
  3. 3.
    Kett DH, Azoulay E, Echeverria PM, et al (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39: 665–670PubMedCrossRefGoogle Scholar
  4. 4.
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309–317PubMedCrossRefGoogle Scholar
  5. 5.
    Horn DL, Neofytos D, Anaissie EJ, et al (2009) Epidemiology and outcomes of candidemia in 2019 patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 48: 1695–1703PubMedCrossRefGoogle Scholar
  6. 6.
    Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3: 772–785PubMedCrossRefGoogle Scholar
  7. 7.
    Sucher AJ, Chahine EB, Balcer HE (2009) Echinocandins: the newest class of antifungals. Ann Pharmacother 43: 1647–1657PubMedCrossRefGoogle Scholar
  8. 8.
    Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41: 1232–1239PubMedCrossRefGoogle Scholar
  9. 9.
    Garey KW, Rege M, Pai MP, et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43: 25–31PubMedCrossRefGoogle Scholar
  10. 10.
    Dalle F, Jouault T, Trinel PA, et al (2003) Beta-1,2-and alpha-1,2-linked oligomannosides mediate adherence of Candida albicans blastospores to human enterocytes in vitro. Infect Immun 71: 7061–7068PubMedCrossRefGoogle Scholar
  11. 11.
    Bendel CM, Hess DJ, Garni RM, Henry-Stanley M, Wells CL (2003) Comparative virulence of Candida albicans yeast and filamentous forms in orally and intravenously inoculated mice. Crit Care Med 31: 501–507PubMedCrossRefGoogle Scholar
  12. 12.
    Dalle F, Wachtler B, Coralie L,et al (2010) Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol 12: 248–271PubMedCrossRefGoogle Scholar
  13. 13.
    Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220: 751–758PubMedCrossRefGoogle Scholar
  14. 14.
    Piarroux R, Grenouillet F, Balvay P, et al (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32: 2443–2449PubMedCrossRefGoogle Scholar
  15. 15.
    Charles PE, Dalle F, Aube H, et al (2005) Candida spp. colonization significance in critically ill medical patients: a prospective study. Intensive Care Med 31: 393–400PubMedCrossRefGoogle Scholar
  16. 16.
    Leon C, Ruiz-Santana S, Saavedra P, et al (2009) Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 37: 1624–1633PubMedCrossRefGoogle Scholar
  17. 17.
    Ostrosky-Zeichner L, Sable C, Sobel J, et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26: 271–276PubMedCrossRefGoogle Scholar
  18. 18.
    Blumberg HM, Jarvis WR, Soucie JM, et al (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33: 177–186PubMedCrossRefGoogle Scholar
  19. 19.
    Playford EG, Lipman J, Kabir M, et al (2009) Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Med 35: 2141–2145PubMedCrossRefGoogle Scholar
  20. 20.
    Leon C, Ruiz-Santana S, Saavedra P, et al (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34: 730–737PubMedCrossRefGoogle Scholar
  21. 21.
    Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2: 1437–1440PubMedCrossRefGoogle Scholar
  22. 22.
    Dupont H, Bourichon A, Paugam-Burtz C, Desmonts JM (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31: 752–757PubMedCrossRefGoogle Scholar
  23. 23.
    Charles PE (2006) Multifocal Candida species colonization as a trigger for early antifungal therapy in critically ill patients: what about other risk factors for fungal infection? Crit Care Med 34: 913–914PubMedCrossRefGoogle Scholar
  24. 24.
    Meyer MH, Letscher-Bru V, Jaulhac B, Waller J, Candolfi E (2004) Comparison of Mycosis IC/F and plus Aerobic/F media for diagnosis of fungemia by the bactec 9240 system. J Clin Microbiol 42: 773–777PubMedCrossRefGoogle Scholar
  25. 25.
    Wahyuningsih R, Freisleben HJ, Sonntag HG, Schnitzler P (2000) Simple and rapid detection of Candida albicans DNA in serum by PCR for diagnosis of invasive candidiasis. J Clin Microbiol 38: 3016–3021PubMedGoogle Scholar
  26. 26.
    Senn L, Robinson JO, Schmidt S, et al (2008) 1,3-b-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 46: 878–885PubMedCrossRefGoogle Scholar
  27. 27.
    Odabasi Z, Mattiuzzi G, Estey E, et al (2004) Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39: 199–205PubMedCrossRefGoogle Scholar
  28. 28.
    Prella M, Bille J, Pugnale M, et al (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 51: 95–101PubMedCrossRefGoogle Scholar
  29. 29.
    Ascioglu S, Rex JH, de Pauw B, et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7–14PubMedCrossRefGoogle Scholar
  30. 30.
    Takesue Y, Kakehashi M, Ohge H, et al (2004) Combined assessment of beta-D-glucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 28: 625–630PubMedCrossRefGoogle Scholar
  31. 31.
    Digby J, Kalbfleisch JH, Glenn A, Larsen A, Browder W, Williams D (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10: 882–885PubMedGoogle Scholar
  32. 32.
    Alam FF, Mustafa AS, Khan ZU (2007) Comparative evaluation of (1, 3)-β-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 7: 103PubMedCrossRefGoogle Scholar
  33. 33.
    Charles PE, Dalle F, Aho S, et al (2006) Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 32: 1577–1583PubMedCrossRefGoogle Scholar
  34. 34.
    Charles PE, Castro C, Ruiz-Santana S, Leon C, Saavedra P, Martin E (2009) Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 35: 2146–2150PubMedCrossRefGoogle Scholar
  35. 35.
    Bochud PY, Chien JW, Marr KA, et al (2008) Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 359: 1766–1777PubMedCrossRefGoogle Scholar
  36. 36.
    Plantinga TS, van der Velden WJ, Ferwerda B, et al (2009) Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 49: 724–732PubMedCrossRefGoogle Scholar
  37. 37.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640–3645PubMedCrossRefGoogle Scholar
  38. 38.
    Pelz RK, Hendrix CW, Swoboda SM, et al (2001) Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 233: 542–548PubMedCrossRefGoogle Scholar
  39. 39.
    Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28: 1708–1717PubMedCrossRefGoogle Scholar
  40. 40.
    Eggimann P, Francioli P, Bille J, et al (1999) Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 27: 1066–1072PubMedCrossRefGoogle Scholar
  41. 41.
    Schuster MG, Edwards JE Jr, Sobel JD, et al (2008) Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 149: 83–90PubMedCrossRefGoogle Scholar
  42. 42.
    Vardakas KZ, Samonis G, Michalopoulos A, Soteriades ES, Falagas ME (2006) Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: a meta-analysis of randomized, placebo-controlled trials. Crit Care Med 34: 1216–1224PubMedCrossRefGoogle Scholar
  43. 43.
    Playford EG, Webster AC, Sorrell TC, Craig JC (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 57: 628–638PubMedCrossRefGoogle Scholar
  44. 44.
    Reboli AC, Rotstein C, Pappas PG, et al (2007) Anidulafungin versus Fluconazole for Invasive Candidias. N Engl J Med 356: 2472–2482PubMedCrossRefGoogle Scholar
  45. 45.
    Mora-Duarte J, Betts R, Rotstein C, et al (2002) Comparison of caspofungin and amphotericin b for invasive candidiasis. N Engl J Med 347: 2020–2029PubMedCrossRefGoogle Scholar
  46. 46.
    Pappas PG, Rotstein CM, Betts RF, et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45: 883–893PubMedCrossRefGoogle Scholar
  47. 47.
    Pappas PG, Kauffman CA, Andes D, et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503–535PubMedCrossRefGoogle Scholar
  48. 48.
    Senn L, Eggimann P, Ksontini R, et al (2009) Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 35: 903–908PubMedCrossRefGoogle Scholar
  49. 49.
    Bougnoux ME, Kac G, Aegerter P, d’Enfert C, Fagon JY, Group CS (2008) Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med 34: 292–299PubMedCrossRefGoogle Scholar
  50. 50.
    Marchetti O, Bille J, Fluckiger U, et al (2004) Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 38: 311–320PubMedCrossRefGoogle Scholar
  51. 51.
    Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 55: 532–538PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • P.-E. Charles
  • R. Bruyere
  • F. Dalle

There are no affiliations available

Personalised recommendations